Seres Gets FDA Approval And The Share Price Goes Down! (NASDAQ:MCRB)

RealPeopleGroup/E+ through Getty Photos

Biotech investing is filled with surprises, generally as a result of analysts have an unsophisticated view as to how difficult doing new stuff may be. Seres (NASDAQ:MCRB) has simply obtained FDA approval for the primary oral (pill) therapy for stopping

5 year good and bad times for Seres share price

Seres 5 12 months share worth chart (In search of Alpha)